|
SI2506857T1
(en)
|
2009-12-01 |
2018-08-31 |
Translate Bio, Inc. |
Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
KR20220025112A
(ko)
|
2011-06-08 |
2022-03-03 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
DE21212055T1
(de)
|
2011-12-07 |
2022-08-04 |
Alnylam Pharmaceuticals, Inc. |
Biologisch abbaubare lipide zur freisetzung von wirkstoffen
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
EP3404103B1
(en)
*
|
2012-02-15 |
2021-03-24 |
CureVac AG |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
EP3348645B1
(en)
*
|
2012-02-15 |
2020-06-03 |
CureVac AG |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120500A1
(en)
*
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
EP3527662B1
(en)
*
|
2012-02-15 |
2022-01-26 |
CureVac AG |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
WO2013143698A1
(en)
*
|
2012-03-27 |
2013-10-03 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
|
ES2660129T3
(es)
|
2012-03-27 |
2018-03-20 |
Curevac Ag |
Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
|
|
DK3260541T3
(da)
*
|
2012-03-27 |
2019-08-12 |
Curevac Ag |
Kunstige nukleinsyremolekyler til forbedret protein- eller preptidekspression
|
|
RU2658490C2
(ru)
|
2012-03-27 |
2018-06-21 |
Кьюрвак Аг |
Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
EP3536787A1
(en)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
PT2922554T
(pt)
*
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
EP3434774A1
(en)
|
2013-01-17 |
2019-01-30 |
ModernaTX, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
|
SG11201506052PA
(en)
|
2013-02-22 |
2015-09-29 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
EA201591229A1
(ru)
|
2013-03-14 |
2016-01-29 |
Шир Хьюман Дженетик Терапис, Инк. |
Способы очистки матричной рнк
|
|
KR102311614B1
(ko)
|
2013-03-14 |
2021-10-08 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Cftr mrna 조성물 및 관련 방법 및 사용
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
CN105517569A
(zh)
*
|
2013-08-21 |
2016-04-20 |
库瑞瓦格股份公司 |
狂犬病疫苗
|
|
SG10201801428RA
(en)
|
2013-08-21 |
2018-03-28 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
|
PL3035955T3
(pl)
*
|
2013-08-21 |
2020-03-31 |
Curevac Ag |
Kompozycja i szczepionka do leczenia raka płuca
|
|
BR112016003361A2
(pt)
*
|
2013-08-21 |
2017-11-21 |
Curevac Ag |
vacina do vírus sincicial respiratório (rsv)
|
|
EP4043032A1
(en)
*
|
2013-08-21 |
2022-08-17 |
CureVac AG |
Rabies vaccine
|
|
AU2014310935B2
(en)
|
2013-08-21 |
2019-11-21 |
CureVac SE |
Combination vaccine
|
|
BR112016000889A2
(pt)
*
|
2013-08-21 |
2017-12-12 |
Curevac Ag |
composição e vacina para tratamento de câncer de próstata
|
|
EP4461365A3
(en)
*
|
2013-08-21 |
2025-02-26 |
CureVac SE |
Respiratory syncytial virus (rsv) vaccine
|
|
AU2014310932B2
(en)
*
|
2013-08-21 |
2019-06-06 |
CureVac SE |
Composition and vaccine for treating lung cancer
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
EP3574923A1
(en)
|
2013-10-22 |
2019-12-04 |
Translate Bio, Inc. |
Mrna therapy for phenylketonuria
|
|
ES2707966T3
(es)
|
2013-10-22 |
2019-04-08 |
Translate Bio Inc |
Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
|
|
WO2015062738A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Gmbh |
Modified rna with decreased immunostimulatory properties
|
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
AU2014375402B2
(en)
|
2013-12-30 |
2020-10-01 |
CureVac SE |
Artificial nucleic acid molecules
|
|
EP3090053B1
(en)
|
2013-12-30 |
2018-11-21 |
CureVac AG |
Artificial nucleic acid molecules
|
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
|
CA2935878C
(en)
|
2014-03-12 |
2023-05-02 |
Curevac Ag |
Combination of vaccination and ox40 agonists
|
|
WO2015149944A2
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Gmbh |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
HRP20220070T1
(hr)
|
2014-04-23 |
2022-04-01 |
Modernatx, Inc. |
Cjepiva nukleinske kiseline
|
|
WO2015162930A1
(ja)
*
|
2014-04-24 |
2015-10-29 |
一般社団法人 医療産業イノベーション機構 |
タンパク質発現を向上させる方法およびタンパク質発現用組成物
|
|
EP4729528A3
(en)
|
2014-04-25 |
2026-06-24 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
SG11201608605QA
(en)
|
2014-06-10 |
2016-12-29 |
Curevac Ag |
Methods and means for enhancing rna production
|
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP4023755B1
(en)
|
2014-12-12 |
2023-04-26 |
CureVac SE |
Artificial nucleic acid molecules for improved protein expression
|
|
BR112017009835A2
(pt)
|
2014-12-30 |
2017-12-26 |
Curevac Ag |
moléculas de ácido nucleico artificiais
|
|
EP4353257A3
(en)
|
2015-04-13 |
2024-08-07 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
US10780054B2
(en)
|
2015-04-17 |
2020-09-22 |
Curevac Real Estate Gmbh |
Lyophilization of RNA
|
|
AU2016251687C1
(en)
|
2015-04-22 |
2023-07-27 |
CureVac SE |
RNA containing composition for treatment of tumor diseases
|
|
WO2016176330A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
WO2016174271A1
(en)
|
2015-04-30 |
2016-11-03 |
Curevac Ag |
Immobilized poly(n)polymerase
|
|
WO2016180430A1
(en)
|
2015-05-08 |
2016-11-17 |
Curevac Ag |
Method for producing rna
|
|
DK3294326T3
(da)
|
2015-05-15 |
2021-05-31 |
Curevac Ag |
Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
|
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
CN107530448A
(zh)
|
2015-05-20 |
2018-01-02 |
库瑞瓦格股份公司 |
包含长链rna的干粉组合物
|
|
EP4098743A1
(en)
|
2015-05-29 |
2022-12-07 |
CureVac AG |
Method for adding cap structures to rna using immobilized enzymes
|
|
DK3303583T3
(da)
|
2015-05-29 |
2020-07-13 |
Curevac Real Estate Gmbh |
Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering
|
|
HUE067372T2
(hu)
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
EP4239080A3
(en)
|
2015-07-01 |
2023-11-01 |
CureVac Manufacturing GmbH |
Method for analysis of an rna molecule
|
|
US10501768B2
(en)
|
2015-07-13 |
2019-12-10 |
Curevac Ag |
Method of producing RNA from circular DNA and corresponding template DNA
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
WO2017025447A1
(en)
|
2015-08-10 |
2017-02-16 |
Curevac Ag |
Method of increasing the replication of a circular dna molecule
|
|
US12258567B2
(en)
*
|
2015-08-28 |
2025-03-25 |
CureVac SE |
Artificial nucleic acid molecules
|
|
HRP20220156T1
(hr)
|
2015-09-17 |
2022-04-15 |
Modernatx, Inc. |
Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
|
|
EP4101930A1
(en)
|
2015-09-17 |
2022-12-14 |
ModernaTX, Inc. |
Polynucleotides containing a stabilizing tail region
|
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017064146A1
(en)
|
2015-10-12 |
2017-04-20 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
|
JP2018530587A
(ja)
|
2015-10-16 |
2018-10-18 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
ｍＲＮＡキャップ類似体およびｍＲＮＡキャッピングの方法
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
|
DK3362461T3
(da)
|
2015-10-16 |
2022-05-09 |
Modernatx Inc |
Mrna-cap-analoger med modificeret phosphatbinding
|
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
|
SG11201803360UA
(en)
|
2015-10-22 |
2018-05-30 |
Modernatx Inc |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
MA45209A
(fr)
|
2015-10-22 |
2019-04-17 |
Modernatx Inc |
Vaccins contre les maladies sexuellement transmissibles
|
|
DE20164728T1
(de)
|
2015-10-22 |
2021-09-30 |
Modernatx, Inc. |
Impfstoffe gegen atemwegsvirus
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
CN108368028B
(zh)
|
2015-10-28 |
2021-09-03 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
EP3374504B1
(en)
|
2015-11-09 |
2025-03-19 |
CureVac SE |
Optimized nucleic acid molecules
|
|
WO2017081110A1
(en)
|
2015-11-09 |
2017-05-18 |
Curevac Ag |
Rotavirus vaccines
|
|
RS63051B1
(sr)
|
2015-12-22 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularnu isporuku agenasa
|
|
WO2017109134A1
(en)
|
2015-12-22 |
2017-06-29 |
Curevac Ag |
Method for producing rna molecule compositions
|
|
EP3394280A1
(en)
|
2015-12-23 |
2018-10-31 |
CureVac AG |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
US12678515B2
(en)
|
2015-12-30 |
2026-07-14 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US12612654B2
(en)
|
2016-02-12 |
2026-04-28 |
CureVac SE |
Method for analyzing RNA
|
|
WO2017140905A1
(en)
*
|
2016-02-17 |
2017-08-24 |
Curevac Ag |
Zika virus vaccine
|
|
EP3423595A1
(en)
|
2016-03-03 |
2019-01-09 |
CureVac AG |
Rna analysis by total hydrolysis
|
|
EP4487869A3
(en)
|
2016-04-22 |
2025-07-30 |
CureVac SE |
Rna encoding a tumor antigen
|
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
|
EP4233898A3
(en)
*
|
2016-05-04 |
2023-11-01 |
CureVac SE |
Influenza mrna vaccines
|
|
EP4631970A3
(en)
|
2016-05-04 |
2026-01-07 |
CureVac SE |
Nucleic acid molecules and uses thereof
|
|
CN115837014A
(zh)
|
2016-05-18 |
2023-03-24 |
摩登纳特斯有限公司 |
编码松弛素的多核苷酸
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
WO2017212007A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
|
US20190336611A1
(en)
|
2016-06-09 |
2019-11-07 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
WO2017212009A1
(en)
|
2016-06-09 |
2017-12-14 |
Curevac Ag |
Hybrid carriers for nucleic acid cargo
|
|
EP3468537A1
(en)
|
2016-06-14 |
2019-04-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN109715205A
(zh)
|
2016-08-19 |
2019-05-03 |
库瑞瓦格股份公司 |
用于癌症治疗的rna
|
|
WO2018041921A1
(en)
|
2016-08-31 |
2018-03-08 |
Curevac Ag |
Mixing device for the production of a liquid nucleic acid composition
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
KR20190093816A
(ko)
*
|
2016-10-26 |
2019-08-26 |
큐어백 아게 |
지질 나노입자 mRNA 백신
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
|
US20180193270A1
(en)
|
2016-11-29 |
2018-07-12 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
WO2018104538A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rna for treatment or prophylaxis of a liver disease
|
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
WO2018115525A1
(en)
*
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
EP3568155A4
(en)
|
2017-01-11 |
2020-09-23 |
The Trustees Of The University Of Pennsylvania |
RNA MODIFIED BY NUCLEOSIDE TO INDUCE AN IMMUNE RESPONSE AGAINST ZIKA VIRUS
|
|
MA47515A
(fr)
|
2017-02-16 |
2019-12-25 |
Modernatx Inc |
Compositions immunogènes très puissantes
|
|
MX2019010155A
(es)
|
2017-02-27 |
2020-12-10 |
Translate Bio Inc |
Arnm de cftr optimizado por codón novedoso.
|
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
CA3050614A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
WO2018170347A1
(en)
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
MX2019011215A
(es)
|
2017-03-24 |
2020-02-12 |
Curevac Ag |
Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
US11596679B2
(en)
|
2017-04-27 |
2023-03-07 |
Vanderbilt University |
Hepatitis C virus gene sequences and methods of use therefor
|
|
US11820728B2
(en)
|
2017-04-28 |
2023-11-21 |
Acuitas Therapeutics, Inc. |
Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
IL270631B2
(en)
|
2017-05-16 |
2024-03-01 |
Translate Bio Inc |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
|
EP3625363A1
(en)
|
2017-05-17 |
2020-03-25 |
CureVac Real Estate GmbH |
Method for determining at least one quality parameter of an rna sample
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
JP7722629B2
(ja)
|
2017-07-04 |
2025-08-13 |
キュアバック エスイー |
新規核酸分子
|
|
JP2020532961A
(ja)
*
|
2017-08-15 |
2020-11-19 |
インテリア セラピューティクス，インコーポレイテッド |
メッセンジャーリボ核酸（ｍＲＮＡ）をコードする安定化された核酸
|
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
JP7461872B2
(ja)
|
2017-08-17 |
2024-04-04 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US20200362382A1
(en)
|
2017-08-18 |
2020-11-19 |
Modernatx, Inc. |
Methods of preparing modified rna
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
US20200208140A1
(en)
*
|
2017-08-31 |
2020-07-02 |
Ohio State Innovation Foundation |
Methods of making and using tandem, twin barcode molecules
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
RNA VACZINE AGAINST ZIKA VIRUS
|
|
BR112020004351A2
(pt)
|
2017-10-19 |
2020-09-08 |
Curevac Ag |
moléculas de ácido nucleico artificial
|
|
SG11202003247RA
(en)
|
2017-11-08 |
2020-05-28 |
Curevac Ag |
Rna sequence adaptation
|
|
US11931406B2
(en)
|
2017-12-13 |
2024-03-19 |
CureVac SE |
Flavivirus vaccine
|
|
CN111511928A
(zh)
|
2017-12-21 |
2020-08-07 |
库瑞瓦格股份公司 |
偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法
|
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
|
CN111778169B
(zh)
*
|
2018-01-31 |
2023-02-10 |
康码（上海）生物科技有限公司 |
一种提高体外蛋白合成效率的方法
|
|
EP3773702A2
(en)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
|
CA3091558A1
(en)
|
2018-04-17 |
2019-10-24 |
Curevac Ag |
Novel rsv rna molecules and compositions for vaccination
|
|
US20210260178A1
(en)
|
2018-06-27 |
2021-08-26 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
CA3102135A1
(en)
|
2018-06-28 |
2020-01-02 |
Curevac Ag |
Bioreactor for rna in vitro transcription
|
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EP3852911B1
(en)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
AU2019384557B2
(en)
|
2018-11-21 |
2025-07-17 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
CA3122645A1
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Methods for rna analysis
|
|
AU2019410737A1
(en)
|
2018-12-21 |
2021-06-10 |
CureVac SE |
RNA for malaria vaccines
|
|
PL3908568T3
(pl)
|
2019-01-11 |
2024-12-02 |
Acuitas Therapeutics, Inc. |
Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
|
|
CN113939282A
(zh)
|
2019-01-31 |
2022-01-14 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
|
KR20210133218A
(ko)
|
2019-01-31 |
2021-11-05 |
모더나티엑스, 인크. |
볼텍스 믹서 및 연계된 방법, 시스템 및 이의 장치
|
|
EP3920950A1
(en)
|
2019-02-08 |
2021-12-15 |
CureVac AG |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
MA55321A
(fr)
|
2019-03-15 |
2022-01-19 |
Modernatx Inc |
Vaccins à base d'arn contre le vih
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
EP4010481A4
(en)
|
2019-08-09 |
2023-09-20 |
Nutcracker Therapeutics, Inc. |
MICROFLUIDIC DEVICE AND METHODS OF USE
|
|
WO2021028439A1
(en)
|
2019-08-14 |
2021-02-18 |
Curevac Ag |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
CA3155003A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
|
CA3162019A1
(en)
|
2019-12-20 |
2021-06-24 |
Gemma NAVARRO |
Lipid nanoparticles for delivery of nucleic acids
|
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
DE202021004130U1
(de)
|
2020-02-04 |
2022-10-26 |
Curevac Ag |
Coronavirus-Vakzine
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
CA3178344A1
(en)
|
2020-03-31 |
2021-10-07 |
The Trustees Of The University Of Pennsylvania |
Universal influenza vaccine using nucleoside-modified mrna
|
|
WO2021204179A1
(en)
|
2020-04-09 |
2021-10-14 |
Suzhou Abogen Biosciences Co., Ltd. |
Nucleic acid vaccines for coronavirus
|
|
TWI899203B
(zh)
|
2020-04-09 |
2025-10-01 |
大陸商蘇州艾博生物科技有限公司 |
脂質奈米粒子組成物
|
|
WO2021239880A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
AU2021301922A1
(en)
|
2020-06-30 |
2023-02-02 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
EP4178544A4
(en)
|
2020-07-08 |
2024-09-25 |
The Trustees of the University of Pennsylvania |
NUCLEOSIDE-MODIFIED RNA TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV-2 VIRUS
|
|
KR20230051172A
(ko)
|
2020-07-16 |
2023-04-17 |
아퀴타스 테라퓨틱스 인크. |
지질 나노 입자에 사용하기 위한 양이온성 지질
|
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
|
TW202214566A
(zh)
|
2020-08-20 |
2022-04-16 |
大陸商蘇州艾博生物科技有限公司 |
脂質化合物及脂質奈米粒子組合物
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
WO2022043551A2
(en)
|
2020-08-31 |
2022-03-03 |
Curevac Ag |
Multivalent nucleic acid based coronavirus vaccines
|
|
MX2023004371A
(es)
|
2020-10-14 |
2023-07-26 |
George Mason Res Foundation Inc |
Lípidos ionizables, y métodos de fabricación y uso de los mismos.
|
|
US20240299309A1
(en)
|
2020-12-22 |
2024-09-12 |
CureVac SE |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
MX2023007574A
(es)
|
2020-12-22 |
2023-09-29 |
CureVac SE |
"vacuna de arn contra variantes de sars-cov-2.
|
|
CN116615472A
(zh)
|
2021-01-14 |
2023-08-18 |
苏州艾博生物科技有限公司 |
聚合物缀合的脂质化合物和脂质纳米颗粒组合物
|
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
CA3170747A1
(en)
|
2021-01-27 |
2022-08-04 |
Moritz THRAN |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
EP4313152A1
(en)
|
2021-03-26 |
2024-02-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
|
EP4312988A2
(en)
|
2021-03-31 |
2024-02-07 |
CureVac SE |
Syringes containing pharmaceutical compositions comprising rna
|
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
|
US20240277872A1
(en)
*
|
2021-05-12 |
2024-08-22 |
The Broad Institute, Inc. |
Modified mrna, modified non-coding rna, and uses thereof
|
|
AU2022281746B2
(en)
|
2021-05-24 |
2025-01-16 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
EP4377331A2
(en)
|
2021-07-30 |
2024-06-05 |
CureVac SE |
Mrnas for treatment or prophylaxis of liver diseases
|
|
EP4763287A2
(en)
|
2021-09-03 |
2026-06-24 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
IL309502A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine
|
|
WO2023044343A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
JP7883580B2
(ja)
|
2021-10-08 |
2026-07-01 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
EP4422698A1
(en)
|
2021-10-29 |
2024-09-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
JP2025502599A
(ja)
|
2021-12-23 |
2025-01-28 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
WO2023122752A1
(en)
|
2021-12-23 |
2023-06-29 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
EP4469091A1
(en)
|
2022-01-28 |
2024-12-04 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
CA3248209A1
(en)
|
2022-05-25 |
2023-11-30 |
CureVac SE |
Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
|
|
JP2025527583A
(ja)
|
2022-08-18 |
2025-08-22 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質ナノ粒子の組成物
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
CN120153078A
(zh)
|
2022-10-27 |
2025-06-13 |
辉瑞大药厂 |
编码rsv-f的rna分子及含所述rna分子的疫苗
|
|
WO2024089229A1
(en)
|
2022-10-28 |
2024-05-02 |
CureVac SE |
Improved formulations comprising lipid-based carriers encapsulating rna
|
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
KR20250153298A
(ko)
|
2023-03-08 |
2025-10-24 |
큐어백 에스이 |
핵산 전달을 위한 신규의 지질 나노입자 제형
|
|
WO2024192291A1
(en)
|
2023-03-15 |
2024-09-19 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
EP4680595A2
(en)
|
2023-03-15 |
2026-01-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
JP2026518411A
(ja)
|
2023-04-27 |
2026-06-08 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
インフルエンザウイルスワクチン
|
|
EP4701657A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
EP4713483A1
(en)
|
2023-05-16 |
2026-03-25 |
CureVac RNA Printer GmbH |
Improved rna in vitro transcription using dna beads
|
|
KR20260018077A
(ko)
|
2023-05-26 |
2026-02-06 |
큐어백 에스이 |
암 항원
|
|
EP4731655A1
(en)
|
2023-06-23 |
2026-04-29 |
CureVac SE |
Nucleic acid encoded antibodies
|
|
WO2025027492A1
(en)
|
2023-07-31 |
2025-02-06 |
Pfizer Inc. |
Coronavirus antigen variants
|
|
WO2025027060A1
(en)
|
2023-07-31 |
2025-02-06 |
CureVac SE |
Nucleic acid encoded runx3 transcription factor
|
|
EP4761761A1
(en)
|
2023-08-16 |
2026-06-24 |
CureVac SE |
Rna conjugates
|
|
EP4771154A2
(en)
|
2023-09-01 |
2026-07-08 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
EP4777526A1
(en)
|
2023-09-12 |
2026-07-22 |
Aadigen, LLC |
Methods and compositions for treating or preventing cancer
|
|
WO2025063261A1
(ja)
|
2023-09-22 |
2025-03-27 |
塩野義製薬株式会社 |
ウイルス由来タンパク質をコードするポリヌクレオチド
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025088088A1
(en)
|
2023-10-27 |
2025-05-01 |
CureVac SE |
Rna composition for improving cell therapy
|
|
WO2025103803A1
(en)
|
2023-11-13 |
2025-05-22 |
CureVac SE |
Immunotherapy against neuronal and brain tumors
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025126019A1
(en)
|
2023-12-13 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025126071A1
(en)
|
2023-12-14 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025134046A1
(en)
|
2023-12-22 |
2025-06-26 |
Pfizer Inc. |
Methods and vaccine compositions for lyme disease
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025242815A1
(en)
|
2024-05-23 |
2025-11-27 |
CureVac SE |
Immunotherapy of squamous cell carcinoma
|
|
WO2026018181A1
(en)
|
2024-07-17 |
2026-01-22 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
WO2026030275A1
(en)
|
2024-08-01 |
2026-02-05 |
Pfizer Inc. |
Rna molecules
|
|
WO2026122685A1
(en)
|
2024-12-03 |
2026-06-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|